An interventional study of MDMA, LSD, psilocybin in Personal Experience of Substance-assisted Therapy Using Psilocybin, MDMA, and LSD, sponsored by Felix Mueller. Enrolling by invitation at 1 site in Switzerland. Open to participants aged 27 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-14.
Sponsored by Felix Mueller · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The study investigates two groups of participants of the SÄPT therapist's training starting in October 2022. The overall objective is to investigate the risks and benefits of personal experience (PE) with substance-induced altered states of consciousness for physicians or psychotherapists in the context of a training course for substance-assisted therapy. Specifically, the study aims to assess changes in therapeutic attitude and other factors important in interactions between patients and therapists (such as empathy and cognitive flexibility).
Felix Mueller is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: MDMA, LSD, psilocybin
Drug pages: N-Methyl-3,4-methylenedioxyamphetamineStudies of N-Methyl-3,4-methylenedioxyamphetamineN-Methyl-3,4-methylenedioxyamphetamine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Lysergic Acid DiethylamideStudies of Lysergic Acid DiethylamideLysergic Acid Diethylamide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · PsilocybinStudies of PsilocybinPsilocybin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
* MDMA per os (2 x 100mg) in a group setting * LSD per os (75 and 150 mcg) in a 1:1 setting * Psilocybin per os (15 mg and 25 mg) in a group setting * Three study days are without drug administration: Participants experience the role of the therapist in a 1:1 setting
TASC-2 scale
The primary endpoint is changes on the TASC-2 scale of the Therapeutic attitude questionnaire (ThAT)
Time frame: Three weeks after last PE
semi-structured interview
A semi-structured interview will be used to explore the range of effects and systematically collect and record subjective effects of the personal experience
Time frame: Five months after last PE
TASC-2 scale
TASC-2 scale of the Therapeutic attitude questionnaire (ThAT)
Time frame: Three weeks after each PE and six months after last PE
SOCS-S
Compassion with self
Time frame: Three weeks after each PE and six months after last PE
SPCS-O
Compassion with others
Time frame: Three weeks after each PE and six months after last PE
SPF/IRI
Empathy questionnaire
Time frame: Three weeks after each PE and six months after last PE
5D-ASC
5 dimensions of altered states of consciousness questionnaire
Time frame: Directly after each PE
CEQ
Challenging experience questionnaire
Time frame: Directly after each PE
APEQ
Acceptance /avoidance-promoting experiences questionnaire
Time frame: Directly after each PE
PIQ
Psychological insights questionnaire
Time frame: Directly after each PE
CSOWD
Connectedness scale
Time frame: Directly after each PE
EBI
Emotional breakthrough inventory
Time frame: Directly after each PE
BFW/E
Berner Subjective Well-Being questionnaire
Time frame: Three weeks after each PE and six months after last PE
PEQ
Persisting effects questionnaire
Time frame: Three weeks after each PE and six months after last PE
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2022 (actual). Primary completion is estimated for Jun 2029, 79 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: N-Methyl-3,4-methylenedioxyamphetamine · Lysergic Acid Diethylamide · Psilocybin
Felix Mueller